Ostarine is the closest SARM to currently being accepted in medication which is now in phase II clinical trials. Like SARMs on the whole, MK-2866 targets androgen receptors over a selective foundation and avoids building the forms of unsafe side effects involved with substances like testosterone, human growth hormone, or https://mikes868qzt0.blog-gold.com/profile